179 related articles for article (PubMed ID: 12902452)
1. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Tu SM; Lin SH; Logothetis C
J Natl Cancer Inst; 2003 Aug; 95(15):1174-5; author reply 1175. PubMed ID: 12902452
[No Abstract] [Full Text] [Related]
2. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Atkins CD
J Natl Cancer Inst; 2003 Feb; 95(4):332; author reply 333-4. PubMed ID: 12591994
[No Abstract] [Full Text] [Related]
3. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Rosenthal M
J Natl Cancer Inst; 2003 Feb; 95(4):332; author reply 333-4. PubMed ID: 12591992
[No Abstract] [Full Text] [Related]
4. Re: A Randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Winquist E; Berry S
J Natl Cancer Inst; 2004 Aug; 96(15):1183; author reply 1183-1184. PubMed ID: 15292391
[No Abstract] [Full Text] [Related]
5. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Berruti A; Tucci M; Terrone C; Scarpa RM; Angeli A; Dogliotti L
J Natl Cancer Inst; 2003 Feb; 95(4):332-3; author reply 333-4. PubMed ID: 12591993
[No Abstract] [Full Text] [Related]
6. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Grenader T; Shavit L; Uziely B; Peretz T
J Natl Cancer Inst; 2005 Feb; 97(3):235-6. PubMed ID: 15687369
[No Abstract] [Full Text] [Related]
7. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Chen B;
J Natl Cancer Inst; 2002 Oct; 94(19):1458-68. PubMed ID: 12359855
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates in prostate cancer: where are we and where should we go?
Saad F
J Natl Cancer Inst; 2003 Sep; 95(17):1262-3. PubMed ID: 12953073
[No Abstract] [Full Text] [Related]
9. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Saad F; Gleason DM; Murray R; Tchekmedyian S; Venner P; Lacombe L; Chin JL; Vinholes JJ; Goas JA; Zheng M;
J Natl Cancer Inst; 2004 Jun; 96(11):879-82. PubMed ID: 15173273
[TBL] [Abstract][Full Text] [Related]
10. Re: Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer.
Parker CC
J Natl Cancer Inst; 2004 Oct; 96(19):1480; author reply 1480-1. PubMed ID: 15467039
[No Abstract] [Full Text] [Related]
11. The use of bisphosphonates in prostate cancer.
Khan MA
BJU Int; 2003 Jul; 92(1):152. PubMed ID: 12823405
[No Abstract] [Full Text] [Related]
12. Clinical trials test bisphosphonates in hormone-sensitive prostate cancer.
Bankhead C
J Natl Cancer Inst; 2003 Sep; 95(17):1273-4. PubMed ID: 12953081
[No Abstract] [Full Text] [Related]
13. Zoledronic acid significantly reduces pathologic fractures in patients with advanced-stage prostate cancer metastatic to bone.
Saad F
Clin Prostate Cancer; 2002 Dec; 1(3):145-52. PubMed ID: 15046689
[TBL] [Abstract][Full Text] [Related]
14. The role of bisphosphonates in hormone-refractory prostate cancer.
Saad F; Karakiewicz P; Perrotte P
World J Urol; 2005 Feb; 23(1):14-8. PubMed ID: 15666171
[TBL] [Abstract][Full Text] [Related]
15. Advances in prevention and treatment of bone metastases in prostate cancer. Role of RANK/RANKL inhibition.
Gomez-Veiga F; Ponce-Reixa J; Martinez-Breijo S; Planas J; Morote J
Actas Urol Esp; 2013 May; 37(5):292-304. PubMed ID: 23246105
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of bisphosphonates in the management of skeletal complications of bone metastases and selection of clinical endpoints.
Major PP; Cook R
Am J Clin Oncol; 2002 Dec; 25(6 Suppl 1):S10-8. PubMed ID: 12562046
[TBL] [Abstract][Full Text] [Related]
17. [The effect of bisphosphonates on bone metastasis of hormone-refractory prostate cancer].
Tanaka T; Kawashima H; Kuratsukuri K; Sugimura K; Nakatani T
Hinyokika Kiyo; 2006 Jun; 52(6):491-4. PubMed ID: 16848364
[TBL] [Abstract][Full Text] [Related]
18. Zoledronic acid: a new advance in managing skeletal events in prostate cancer.
Kirby RS
BJU Int; 2003 Apr; 91(6):464-5. PubMed ID: 12656892
[No Abstract] [Full Text] [Related]
19. Treatment of bone complications in advanced prostate cancer: rationale for bisphosphonate use and results of a phase III trial with zoledronic acid.
Saad F
Semin Oncol; 2002 Dec; 29(6 Suppl 21):19-27. PubMed ID: 12584691
[TBL] [Abstract][Full Text] [Related]
20. [Use of zoledronic acid for high risk prostate cancer patients].
Rexer H
Urologe A; 2005 Feb; 44(2):183-4. PubMed ID: 15793897
[No Abstract] [Full Text] [Related]
[Next] [New Search]
